Derrell Porter Sells Acumen Pharmaceuticals Shares
Derrell Porter sold 12,800 shares of Acumen Pharmaceuticals on June 16, 2026.
Key Points
- Derrell Porter sold 12,800 shares of Acumen Pharmaceuticals at $2.33 each, totaling $29,824.
- Shares of NasdaqGS:ABOS traded at $2.33, with a 52-week range between $1.10 and $3.60.
- Analysts maintain a strong buy consensus with a mean target price of $7.40.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Derrell Porter, associated with Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS), sold 12,800 shares of the company on June 16, 2026. The shares were sold at an average price of $2.33, amounting to a total transaction value of $29,824. This sale was not part of a pre-planned trading program.
Other Institutional Activity in Acumen Pharmaceuticals
RA Capital Management, L.P. grew its holdings by 6,060,606 shares, ending with 20,992,669 shares valued at about $49.5 million. Sands Capital Alternatives, LLC added 303,030 shares, bringing its total to 3,720,105 shares worth approximately $8.78 million. Alyeska Investment Group, L.P. significantly increased its position by 1,515,151 shares, now holding 2,454,754 shares valued at roughly $5.78 million. Franklin Resources Inc maintained its position with 2,305,096 shares valued at $5.44 million. Adar1 Capital Management, LLC also boosted its stake by 1,265,151 shares to a total of 2,156,334 shares, valued at around $5.09 million.
Acumen Pharmaceuticals, Inc. Stock Down 21.7%
Shares of NasdaqGS:ABOS traded near $2.33. Acumen Pharmaceuticals has a market cap of approximately $162.5 million. The company's stock has a 52-week low of $1.10 and a 52-week high of $3.60. It has a 50-day moving average of $2.46 and a 200-day moving average of $2.23. Acumen's current ratio is 4.55, with a quick ratio of 4.43 and a debt-to-equity ratio of 35.62.
Recent Earnings
Acumen Pharmaceuticals is expected to report its next earnings on August 11, 2026. The company is not currently profitable, with an EPS of -$1.85 and a return on equity of -93.23%. The net margin is currently at 0%.
Analysts Set New Price Targets
On March 17, 2026, BTIG maintained its buy rating on Acumen Pharmaceuticals with a price target of $8. The overall analyst consensus remains strong buy, with a mean target price of $7.40 based on five analyst opinions.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease. Headquartered in Newton, Massachusetts, the company is working on a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 clinical trial. The company collaborates with Halozyme, Inc. and JCR Pharmaceuticals Co. Ltd to advance its treatment strategies.
Bottom Line
Derrell Porter's sale of Acumen Pharmaceuticals shares is a notable insider transaction, reflecting activity within the company. Investors often watch insider transactions for potential insights into company sentiment. However, it's important to remember that these transactions are disclosed after the fact and may not indicate future performance.
Get Acumen Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.